---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000077"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-08-19T11:01:13+00:00"
generated_at: "2026-08-19T11:05:13.674041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora licenses South Korean rights for KIO-301 to CKD for $1M upfront plus milestones and royalties

## Summary
- $1M upfront payment from CKD for exclusive South Korean rights to KIO-301 for retinitis pigmentosa and other ophthalmic indications.
- Eligible for development, regulatory, and sales milestone payments plus double-digit royalties on net sales in South Korea.
- CKD to handle development and commercialization in South Korea; partners Théa, Senju, and CKD to coordinate single global Phase 3 trial.
- Kiora to focus on KIO-104 and ion channel modulators; evaluating strategic transactions to expand pipeline.

## SEC filing metadata
- accession: 0001372514-26-000077
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-08-19T11:01:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/0001372514-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/kprx-20260819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000077
- JSON: https://secwatch.observer/filing/0001372514-26-000077.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.